Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 952,300 shares, an increase of 14.4% from the December 31st total of 832,200 shares. Based on an average trading volume of 94,200 shares, the short-interest ratio is presently 10.1 days. Currently, 4.4% of the shares of the company are sold short.
Gyre Therapeutics Stock Performance
Shares of GYRE traded up $0.79 during trading hours on Wednesday, reaching $12.67. The company had a trading volume of 43,049 shares, compared to its average volume of 94,438. Gyre Therapeutics has a 12-month low of $8.26 and a 12-month high of $26.37. The firm has a 50 day simple moving average of $11.09 and a 200-day simple moving average of $12.45.
Insider Activity
In related news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares in the company, valued at $37,191,530.90. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 26,054 shares of company stock valued at $295,237 over the last quarter. Corporate insiders own 19.52% of the company's stock.
Institutional Trading of Gyre Therapeutics
A number of institutional investors have recently bought and sold shares of the company. FMR LLC purchased a new stake in shares of Gyre Therapeutics in the 3rd quarter worth about $47,000. Barclays PLC raised its position in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after purchasing an additional 6,855 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Gyre Therapeutics during the 2nd quarter valued at $166,000. Bank of New York Mellon Corp increased its position in Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock worth $168,000 after buying an additional 1,389 shares in the last quarter. Finally, Advantage Alpha Capital Partners LP acquired a new position in shares of Gyre Therapeutics in the third quarter worth $334,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
